Genflow Biosciences PLC
08 September 2026
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Genflow Biosciences Plc
8 September 2026
Genflow Meets Primary Endpoint in SLAB Clinical Trial
Detailed Trial Results to be Presented at the Animal Longevity Summit 2026
Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases, announces that its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial, evaluating its proprietary SIRT6 centenarian gene therapy in aged dogs, has met its primary endpoint. The Company further announces that detailed results from the completed trial will be presented at the Animal Longevity Summit ("ALOS") in Toronto, Canada, on 1-2 October 2026.
Primary endpoint met
The SLAB clinical trial, a randomized, blinded trial, enrolled 24 beagle dogs aged over 10 years allocated to four groups: two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 group, and a saline control group.
The SLAB clinical trial met its primary endpoint of reduction in biological age measured by the GRIM methylation clock. Treated animals demonstrated a clear signal of improvement relative to control animals.
These results build on the positive preliminary interim muscle data reported in February 2026 and the sustained safety and efficacy confirmed at the three-month follow-up in April 2026.
Detailed results to be presented at the Animal Longevity Summit 2026
Alongside the primary endpoint, improvements were observed across multiple functional and observable secondary measures. The Company's key mechanistic analyses will be presented publicly for the first time at ALOS in Toronto on October 2, 2026.
ALOS is the first conference dedicated exclusively to animal longevity, bringing together leading researchers, veterinary scientists, biotechnology companies and investors focused on extending healthy lifespan in companion animals. Confirmed speakers include Dr Matt Kaeberlein, Dr Vera Gorbunova, Dr Aubrey de Grey, Liz Parrish, Dr Noah Davidsohn and Dr Varun Dwaraka. Genflow's presentation is expected to represent the most comprehensive dataset generated to date from the Company's veterinary longevity programme.
Commercial and strategic implications
Genflow believes that achievement of the primary endpoint validates the potential of its SIRT6 centenarian naked DNA therapy as a first-in-class approach to addressing age-related decline in companion animals and materially strengthens the program's relevance to prospective animal health partners. The Company continues to engage with Tier-1 global animal health companies regarding potential licensing, co-development and commercialization opportunities, and will update the market as appropriate.
Dr Eric Leire, Chief Executive Officer of Genflow Biosciences, said: "Meeting the primary endpoint in SLAB is a defining milestone for Genflow. We set out to demonstrate that our centenarian SIRT6 naked DNA therapy could measurably address age-related decline in a real-world aging mode. This provides a powerful foundation for our partner discussions across animal health. We look forward to sharing the full dataset, including the critical methylation clock and muscle histology results, with the scientific and investment communities at the Animal Longevity Summit in October."
Contacts
Genflow Biosciences Plc
Dr Eric Leire, Chief Executive Officer
+32-477-495-881
ON365 Partners Inc.
Eric Laub, Investor Relations
+1 617-444-9509
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is a persistent unmet medical need. Genflow is also advancing an ophthalmology program, GF-1006, an mRNA-based SIRT6 therapy targeting corneal pathologies and glaucoma - a leading cause of irreversible blindness for which current treatments reduce intraocular pressure but do not prevent degeneration of the optic nerve. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
END
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.